Rational Combinations 360°

June 23-24, 2016
Park Lane Hotel • New York, New York

Presented by The Conference Forum in collaboration with the Society for Immunotherapy of Cancer

The Conference Forum hosted the inaugural Rational Combinations 360° program, addressing novel clinical trial designs, scientific developments and business aspects related to combination immunotherapies.

With promising cancer immunotherapies in the clinic and an encouraging pipeline of new targets being developed, additional research is now under way to determine the most effective rational combinations that are personalized for individual patients and for specific tumors types. Both small and large companies are now working to bring game-changing combination therapies to the market. As a result, novel therapies and innovative trial designs are creating increased momentum for investment/business development opportunities.

Designed by lead advisor Ian McCaffery, PhD (Corvus Pharmaceuticals), along with advisory board members Axel Hoos, MD, PhD (GSK), Michael Kalos, PhD (Eli Lilly), Patricia Marinello, PhD (Merck) and Omid Hamid, MD (The Angeles Clinic and Research Institute), this program provided up-to-date information on combination developments that will aid in identifying the best cancer treatments for individual patients and tumor types. SITC President, Howard L. Kaufman, MD, FACS, was among several SITC members speaking at this program.